Clinical features of pediatric liver/small bowel transplantation patients with EBV− PTLD
| Case . | Sex/age . | Underlying disease . | Immunosuppressive regimen . | Interval to PTLD, mo* . | Sites of involvement by PTLD . | Treatment . | Follow-up, mo† . | Outcome . |
|---|---|---|---|---|---|---|---|---|
| 1 | F/7 y | Small bowel lymphangiectasia | TAC + prednisone | 9 | TA, LN, BM | Dexamethasone, thalidomide | 128 | ANED |
| 2 | M/16 mo | Gastroschisis | TAC + prednisone | 9 | TA, LN, L, BM | NT | 0.5 | DOC |
| 3 | F/3 y | Intrauterine bowel volvulus | TAC + prednisone | 15 | LN | Dexamethasone | 91 | ANED |
| 4 | F/5 y | Intestinal atresia | TAC + prednisone | 15 | LN, ASB, BM | Dexamethasone | 82 | ANED |
| 5 | M/ 3y | Microvillous inclusion disease | TAC + prednisone | 22 | TA, LN | Dexamethasone, prednisone | 75 | ANED |
| Case . | Sex/age . | Underlying disease . | Immunosuppressive regimen . | Interval to PTLD, mo* . | Sites of involvement by PTLD . | Treatment . | Follow-up, mo† . | Outcome . |
|---|---|---|---|---|---|---|---|---|
| 1 | F/7 y | Small bowel lymphangiectasia | TAC + prednisone | 9 | TA, LN, BM | Dexamethasone, thalidomide | 128 | ANED |
| 2 | M/16 mo | Gastroschisis | TAC + prednisone | 9 | TA, LN, L, BM | NT | 0.5 | DOC |
| 3 | F/3 y | Intrauterine bowel volvulus | TAC + prednisone | 15 | LN | Dexamethasone | 91 | ANED |
| 4 | F/5 y | Intestinal atresia | TAC + prednisone | 15 | LN, ASB, BM | Dexamethasone | 82 | ANED |
| 5 | M/ 3y | Microvillous inclusion disease | TAC + prednisone | 22 | TA, LN | Dexamethasone, prednisone | 75 | ANED |
ANED indicates alive, no evidence of disease; ASB, allograft small bowel; DOC, died of other cause; F, female; L, lungs; LN, lymph nodes; M, male; NT, no therapy; TA, tonsils and adenoids; and TAC, tacrolimus.
Interval between organ transplantation and development of PTLD.
Interval between PTLD diagnosis and last follow-up.